Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG

References

• Auewarakul CU, Promsuwicha O, U-Pratya Y, et al. Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol. 2003;21(3):153.
   PubMed Web of Science ®Google Scholar
• Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690–1696.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–121.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–1405.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all- trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137–5146.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–4725.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Acute Myeloid Leukemia (version 2.2022). [cited 8 Aug 2022]. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
   Google Scholar
• Taylor FB, Toh CH, Hoots WK, et al. Scientific subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330.
   PubMed Web of Science ®Google Scholar
• Zhu H-H, Ma Y-F, Yu K, et al. Early death and survival of patients with acute promyelocytic leukemia in ATRA plus arsenic era: a population-based study. Front Oncol. 2021;11:762653.
   PubMedGoogle Scholar
• Yedla RP, Bala SC, Pydi VR, et al. Outcomes in adult acute promyelocytic leukemia: a decade experience. Clin Lymph Myeloma Leuk. 2020;20(4):e158–e164.
   PubMed Web of Science ®Google Scholar
• Dayama A, Dass J, Seth T, et al. Clinico-hematological profile and outcome of acute promyelocytic leukemia patients at a tertiary care center in North India. Indian J Cancer. 2015;52(3):309.
   PubMed Web of Science ®Google Scholar
• Bajpai J, Sharma A, Kumar L, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian J Cancer. 2011;48(3):316.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martı́n G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015–3021.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014–1021.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627–2632.
   PubMed Web of Science ®Google Scholar
• Coutre SE, Othus M, Powell B, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014;165(4):497–503.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Rahman F, Kabir AL, Khan MR, et al. Disseminated intravascular coagulation in acute promyelocytic leukaemia and its impact on the induction failure: a single centre study. Bangl Med Res Counc Bull. 2013;39(2):57–60.
   PubMedGoogle Scholar
• Baysal M, Gürsoy V, Hunutlu FC, et al. The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study. Ann Hematol. 2022;101(5):1049–1057.
   PubMed Web of Science ®Google Scholar
• Matsuda K, Jo T, Toyama K, et al. Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan. Ann Hematol. 2021;100(10):2613–2619.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Coco FL, Martın G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32(2):89–95.
   PubMed Web of Science ®Google Scholar
• Minamiguchi H, Fujita H, Atsuta Y, et al. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020;99(12):2787–2800.
   PubMed Web of Science ®Google Scholar
• Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187(2):157–162.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–1134.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–1254.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer. 2012;118(23):5811–5818.
   PubMed Web of Science ®Google Scholar
• Zhu H-H, Wu D-P, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4221.
   PubMed Web of Science ®Google Scholar
• Zhu H-H, Wu D-P, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879.
   PubMed Web of Science ®Google Scholar
• Zhu H-H, Liu Y-R, Jia J-S, et al. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987–2989.
   PubMed Web of Science ®Google Scholar
• Sasijareonrat N, Jahn N, Ungprasert P, et al. Efficacy and the adverse effects of oral versus intravenous arsenic for acute promyelocytic leukemia: a meta-analysis of randomized-controlled studies. Technol Cancer Res Treat. 2020;19:1533033820937008.
   Web of Science ®Google Scholar